Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity (2016 - 2020)
Larimar Therapeutics (LRMR) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $92.9 million as the latest value for Q3 2019.
- For the quarter ending Q3 2019, Liabilities and Shareholders Equity fell 29.6% year-over-year to $92.9 million, compared with a TTM value of $307.0 million through Dec 2019, down 27.97%, and an annual FY2018 reading of $121.8 million, up 15.4% over the prior year.
- Liabilities and Shareholders Equity was $92.9 million for Q3 2019 at Larimar Therapeutics, down from $103.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $236.7 million in Q1 2015 and bottomed at $79.8 million in Q2 2018.
- Average Liabilities and Shareholders Equity over 5 years is $137.8 million, with a median of $121.8 million recorded in 2018.
- The sharpest move saw Liabilities and Shareholders Equity surged 62.52% in 2015, then plummeted 32.55% in 2017.
- Year by year, Liabilities and Shareholders Equity stood at $189.1 million in 2015, then plummeted by 30.4% to $131.6 million in 2016, then dropped by 19.84% to $105.5 million in 2017, then grew by 15.4% to $121.8 million in 2018, then decreased by 23.71% to $92.9 million in 2019.
- Business Quant data shows Liabilities and Shareholders Equity for LRMR at $92.9 million in Q3 2019, $103.9 million in Q2 2019, and $110.2 million in Q1 2019.